The Effects of L-carnitine in Reducing Hepatotoxicity of Statins in Rats
Sažetak
Прва линија лечења хиперлипидемије су статистике. Од ове групе, аторвастатин је најпопуларнији и најефикаснији лек. Хепатичка токсичност и миопатија су два примећена нежељена дејства статистике. Активни облик карнитина је Л-карнитин, једињење растворљиво у води које се налази у храни, телу и већини додатака исхрани. Постоји много употреба за Л-карнитин у људском телу. Она помаже у уклањању слободних радикала из организма и снижава производњу водоник пероксида, а оба могу да се чувају од нежељених ефеката јетре које су донели статистике. Осамдесет пацова је насумично подељено у четири главне групе: контролу, Л-карнитин, аторвастатин и комбинацију (Л-карнитин + аторвастатин) група. Ове групе су биле подререне у три подгрупе на основу разлииитих доза лекова. Л -карнитинска група је подељена на L200, L300 и L400. Аторвастатин група је подељена на A10, A15 и A20. Комбинована група је подререна у AL10/200, AL15/300 и AL20/400. Све групе су свакодневно добијале третмане у периоду од месец дана. Према нашим сазнањима, ефекти Л-карнитина (200 мг/кг дневно) на повећање АСТ-а које доноси аторвастатин нису статистички значајни, иако су значајни на повећања у АЛТ, АЛП и ТСБ. Л -карнитин и даље има знатне утицаје на АЛТ, АЛП и ТСБ чак и у већим дозама, док су његови утицаји на ниво АСТ-а постали значајни.
Reference
1. Jose MA, Anandkumar S, Narmadha MP, Sandeep M. A comparative effect of atorvastatin with other statins in patients of hyperlipidemia. Indian journal of pharmacology. 2012 Mar;44(2):261. https://doi.org/10.4103/0253-7613.93864
2. Sadighara M, Joktaji JP, Hajhashemi V, Minaiyan M. Protective effects of coenzyme Q10 and L-carnitine against statin-induced pancreatic mitochondrial toxicity in rats. Research in Pharmaceutical Sciences. 2017 Dec;12(6):434. https://doi.org/10.4103/1735-5362.217424
3. Almukhtar HM, Faisal IM, Merkhan MM. Acute effect of atorvastatin in comparison with rosuvastatin on glucose homeostasis in hypercholesteremic patients. Pharmacology. 2021;25:25-34.
4. Björnsson ES. Hepatotoxicity of statins and other lipid‐lowering agents. Liver International. 2017 Feb;37(2):173-8. https://doi.org/10.1111/liv.13308
5. Jose J. Statins and its hepatic effects: Newer data, implications, and changing recommendations. Journal of Pharmacy & bioallied sciences. 2016 Jan;8(1):23. https://doi.org/10.4103/0975-7406.171699
6. Bang CN, Okin PM. Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Current cardiology reports. 2014 Mar;16:1-5. https://doi.org/10.1007/s11886-013-0461-4
7. Karahalil B, Hare E, Koç G, Uslu İ, Şentürk K, Özkan Y. Hepatotoxicity associated with statins. Arhiv za higijenu rada i toksikologiju. 2017 Dec 20;68(4):254-60. https://doi.org/10.1515/aiht-2017-68-2994
8. Cheon DY, Jo SH. Adverse effects of statin therapy and their treatment. Cardiovascular Prevention and Pharmacotherapy. 2022 Jan 20;4(1):1-6. https://doi.org/10.36011/cpp.2022.4.e4
9. Sun Q, Li L, Zhou Q. Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats. Drug Design, Development and Therapy. 2022 May 17:1473-81.
10. Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterology & hepatology. 2013 Sep;9(9):605.
11. Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced liver injury patterns: a clinical review. Journal of Clinical and Translational Hepatology. 2022 Jun 6;10(3):543. https://doi.org/10.14218/JCTH.2021.00271
12. Kalantari S, Naghipour M. Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. Advanced Biomedical Research. 2014;3. https://doi.org/10.4103/2277-9175.139133
13. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. Journal of hepatology. 2012 Feb 1;56(2):374-80. https://doi.org/10.1016/j.jhep.2011.07.023
14. Niedbalska-Tarnowska J, Ochenkowska K, Migocka-Patrzałek M, Dubińska-Magiera M. Assessment of the Preventive Effect of L-carnitine on Post-statin Muscle Damage in a Zebrafish Model. Cells. 2022 Apr 11;11(8):1297. https://doi.org/10.3390/cells11081297
15. Pirmadah F, Ramezani-Jolfaie N, Mohammadi M, Talenezhad N, Clark CC, Salehi-Abargouei A. Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials. European journal of nutrition. 2020 Aug;59:1767-83. https://doi.org/10.1007/s00394-019-02068-4
16. Li N, Zhao H. Role of carnitine in non-alcoholic fatty liver disease and other related diseases: An update. Frontiers in Medicine. 2021 Aug 9;8:689042. https://doi.org/10.3389/fmed.2021.689042
17. Ko J, Wong EY, Tran HN, Tran RJ, Cao DX. The glycemic, cholesterol, and weight effects of L-carnitine in diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Epidemiology and Management. 2022 Nov 23:100122. https://doi.org/10.1016/j.deman.2022.100122
18. Gao X, Tian Y, Randell E, Zhou H, Sun G. Unfavorable associations between serum trimethylamine N-oxide and L-carnitine levels with components of metabolic syndrome in the Newfoundland population. Frontiers in endocrinology. 2019 Mar 26;10:168. https://doi.org/10.3389/fendo.2019.00168
19. Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Volti GL, Galvano F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism. 2009 Nov 1;58(11):1618-23. https://doi.org/10.1016/j.metabol.2009.05.014
20. Mancilla RF, Lindeboom L, Grevendonk L, Hoeks J, Koves TR, Muoio DM, Schrauwen P, Schrauwen-Hinderling V, Hesselink MK. Skeletal muscle mitochondrial inertia is associated with carnitine acetyltransferase activity and physical function in humans. JCI insight. 2023 Jan 1;8(1). https://doi.org/10.1172/jci.insight.163855
21. Mohamed B, Fares NH, Ashaat NA, Abozeid F. Biochemical, Histological, and Immunohistochemical Changes Associated with Alcl3-Induced Hepatic Injury in Rats: Protective Effects of L-carnitine. Egyptian Journal of Histology. 2022 Mar 1;45(1):90-100. https://doi.org/10.21608/EJH.2021.52300.1395
22. Abdoli N, Azarmi Y, Eghbal MA. Mitigation of statins-induced cytotoxicity and mitochondrial dysfunction by L-carnitine in freshly-isolated rat hepatocytes. Research in Pharmaceutical Sciences. 2015 Mar;10(2):143.
23. Samulak JJ, Sawicka AK, Hartmane D, Grinberga S, Pugovics O, Lysiak-Szydlowska W, Olek RA. L-carnitine supplementation increases trimethylamine-N-oxide but not markers of atherosclerosis in healthy aged women. Annals of Nutrition and Metabolism. 2019 Feb 7;74(1):11-7. https://doi.org/10.1159/000495037
24. Sawicka AK, Renzi G, Olek RA. The bright and the dark sides of L-carnitine supplementation: a systematic review. Journal of the International Society of Sports Nutrition. 2020 Sep 21;17(1):49.https://doi.org/10.1186/s12970-020-00377-2
25. Zhao JV, Burgess S, Fan B, Schooling CM. L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. BMC medicine. 2022 Dec;20(1):1-0. https://doi.org/10.1186/s12916-022-02477-z
26. Du J, Miao M, Lu Z, Chen H, Bao A, Che B, Zhang J, Ju Z, Xu T, He J, Zhang Y. Plasma l-carnitine and risks of cardiovascular events and recurrent stroke after ischemic stroke: A nested case-control study. Nutrition, Metabolism and Cardiovascular Diseases. 2022 Nov 1;32(11):2579-87. https://doi.org/10.1016/j.numecd.2022.08.016
27. Savic D, Hodson L, Neubauer S, Pavlides M. The importance of the fatty acid transporter L-carnitine in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020 Jul 22;12(8):2178. https://doi.org/10.3390/nu12082178
28. Flores‐Guerrero JL, Post A, van Dijk PR, Connelly MA, Garcia E, Navis G, Bakker SJ, Dullaart RP. Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease. Liver International. 2021 Oct;41(10):2371-82.https://doi.org/10.1111/liv.14963
29. Oktaviono YH, Lamara AD, Saputra PB, Arnindita JN, Pasahari D, Saputra ME, Suasti NM. The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: A literature review. Biomolecules and Biomedicine. 2023 Jun 13. https://doi.org/10.17305/bb.2023.8893
30. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine. 2013 May;19(5):576-85. https://doi.org/10.1038/nm.3145
31. Ebrahimi M, Ahangar N, Zamani E, Shaki F. L-Carnitine Prevents Behavioural Alterations in Ketamine-Induced Schizophrenia in Mice: Possible Involvement of Oxidative Stress and Inflammation Pathways. Journal of Toxicology. 2023 Jun 16;2023.
https://doi.org/10.1155/2023/9093231
32. Essawy AE, El-Sayed SA, Tousson E, Abd El-gawad HS, Alhasani RH, Abd Elkader HT. Anti-kindling effect of Ginkgo biloba leaf extract and L-carnitine in the pentylenetetrazol model of epilepsy. Environmental Science and Pollution Research. 2022 Jul;29(32):48573-87. https://doi.org/10.1007/s11356-022-19251-6
33. Kabirifar R, Khodarahmi A, Karimollah A, Moradi A. The preventive effect of atorvastatin on liver fibrosis in the bile duct ligation rats via antioxidant activity and down-regulation of Rac1 and NOX1. Iranian Journal of Basic Medical Sciences. 2020 Jan;23(1):30. https://doi.org/10.22038/IJBMS.2019.33663.8047
34. Faki HE, Tras B, Uney K. Alpha lipoic acid and vitamin E improve atorvastatin-induced mitochondrial dysfunctions in rats. Mitochondrion. 2020 May 1;52:83-8. https://doi.org/10.1016/j.mito.2020.02.011
35. Goodarzi Z, Karami E, Yousefi S, Dehdashti A, Bandegi AR, Ghanbari A. Hepatoprotective effect of atorvastatin on Cadmium chloride induced hepatotoxicity in rats. Life sciences. 2020 Aug 1;254:117770. https://doi.org/10.1016/j.lfs.2020.117770
36. Bishop ML. Clinical Chemistry: Principles, Techniques, and Correlations, Enhanced Edition: Principles, Techniques, and Correlations. Jones & Bartlett Learning; 2020 Jun 11.
37. Aghaa OB, Hamad HT. The correlation between L-carnitine uptake and some hematological parameters in oxidative stressed rats. MMSL. 2022;91(4):318-23. https://doi.org/10.31482/mmsl.2022.007
38. Demiroren K, Dogan Y, Kocamaz H, Ozercan IH, Ilhan S, Ustundag B, Bahcecioglu IH. Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clinics and research in hepatology and gastroenterology. 2014 Feb 1;38(1):63-72. https://doi.org/10.1016/j.clinre.2013.08.014
39. Oh H, Park CH, Jun DW. Impact of L-carnitine supplementation on liver enzyme normalization in patients with chronic liver disease: a meta-analysis of randomized trials. Journal of Personalized Medicine. 2022 Jun 27;12(7):1053. https://doi.org/10.3390/jpm12071053
40. Wu Q, Zhang X, Zhao Y, Yang X. High l-carnitine ingestion impairs liver function by disordering gut bacteria composition in mice. Journal of agricultural and food chemistry. 2020 Apr 28;68(20):5707-14. https://doi.org/10.1021/acs.jafc.9b08313
41. Zhang L, Wu Q, Wang N, Zhang L, Yang X, Zhao Y. Quercetin inhibits hepatotoxic effects by reducing trimethylamine-N-oxide formation in C57BL/6J mice fed with a high l-carnitine diet. Food & Function. 2023;14(1):206-14. https://doi.org/10.1039/D2FO01909D
42. Askarpour M, Djafarian K, Ghaedi E, Sadeghi O, Sheikhi A, Shab-Bidar S. Effect of L-carnitine supplementation on liver enzymes: a systematic review and meta-analysis of randomized controlled trials. Archives of Medical Research. 2020 Jan 1;51(1):82-94. https://doi.org/10.1016/j.arcmed.2019.12.005
43. Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, Lay-Flurrie S, Koshiaris C, McManus RJ, Hobbs FR, Sheppard JP. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. Bmj. 2021 Jul 15;374. https://doi.org/10.1155/2018/7092414
44. Liang X, He Q, Zhao Q. Effect of stains on LDL reduction and liver safety: a systematic review and meta-analysis. BioMed research international. 2018 Mar 5;2018. https://doi.org/10.1155/2018/7092414
45. Pastori D, Pani A, Di Rocco A, Menichelli D, Gazzaniga G, Farcomeni A, D'Erasmo L, Angelico F, Del Ben M, Baratta F. Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis. British Journal of Clinical Pharmacology. 2022 Feb;88(2):441-51. https://doi.org/10.1111/bcp.14943
46. Muñoz AE, Pollarsky F, Marino M, Cartier M, Míguez C, Vázquez H, Álvarez D, Salgado P, Romero G. Safety of chronic simvastatin treatment in patients with decompensated cirrhosis: many adverse events but no liver injury. Digestive Diseases and Sciences. 2021 Sep;66:3199-208. https://doi.org/10.1007/s10620-020-06630-7
47. Ahmed EA, Abd-Eldayem AM, Aboulhagag NA. The possible protective effects of vitamin D and l-carnitine against used atorvastatin-induced myopathy and hepatotoxicity. Comparative Clinical Pathology. 2019 Dec;28:1751-9. https://doi.org/10.1007/s00580-019-03016-8
48. Ahmed SA, Abd El Reheem MH, Elbahy DA. L-Carnitine ameliorates the osteoporotic changes and protects against simvastatin induced myotoxicity and hepatotoxicity in glucocorticoid-induced osteoporosis in rats. Biomedicine & Pharmacotherapy. 2022 Aug 1;152:113221. https://doi.org/10.1016/j.biopha.2022.113221